AEON Biopharma advances ABP-450 biosimilar program, secures $20M funding

AEON Biopharma, Inc.

Pursuing 351(k) biosimilar pathway for ABP-450 with BOTOX as reference product for all therapeutic indications.
Initiated primary analytical studies in Q4 2024; plans BPD Type 2a meeting with FDA in H2 2025.
Closed $20M public offering in Jan 2025; ~89% of Series B warrants exercised as of March 21, 2025.
No specific FY2024 financial results disclosed in the press release; focus on development and funding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.